Viatris Inc. has completed its acquisition of Pacira BioSciences, Inc., a company focused on non-opioid pain management. The transaction was finalized on November 17, 2026, following the successful completion of a tender offer.

On October 8, 2026, Viatris entered into an Agreement and Plan of Merger with Pacira and its wholly owned subsidiary, Peach Purchaser Sub Inc. The tender offer commenced on October 30, 2026, with an offer price of $36.50 per share in cash, net of applicable withholding taxes and without interest.

The tender offer expired at one minute after 11:59 p.m., Eastern Time, on November 16, 2026. According to the depositary agent Equiniti Trust Company, LLC, approximately 32,929,780 shares were validly tendered and not withdrawn, representing about 66.46% of the outstanding shares.

Following the expiration of the tender offer, all conditions were satisfied or waived. Peach Purchaser Sub Inc. accepted for payment all validly tendered shares. The remaining shares were acquired by Viatris and converted into the right to receive the $36.50 per share payment. The merger was completed without a vote of Pacira’s stockholders, with Pacira continuing as a wholly owned subsidiary of Viatris.

The aggregate amount to be paid by Viatris in the offer and merger is approximately $1.69 billion, excluding related fees and expenses. The company plans to fund the acquisition using a combination of cash on hand and short-term borrowings.

In connection with the completion of the transaction, Pacira’s shares will be delisted from the Nasdaq Global Select Market. Viatris expects the acquisition to contribute total revenues of between $90 million and $100 million for the remainder of 2026, specifically for the period from November 17, 2026, through December 31, 2026.